According to the research report titled ‘United States Self-Monitoring Blood Glucose (SMBG) Market Analysis 2015 - 2020 and Industry Forecast 2021 – 2027’, available with MarketStudyReport, United States self-monitoring blood glucose (SMBG) market is expected to accumulate USD 4.6 billion by the end of the forecast period 2021-2027.
 

As per the report findings, increasing number of patients suffering from diabetes, surge in aging population, rapid uptake of user-friendly, innovative & technologically advanced products, and rising risk factors that cause diabetes are propelling the growth of United States self-monitoring blood glucose (SMBG) market.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3140355/
 

As per the American Diabetes Association, in 2017, the estimated total cost of diagnosed diabetes was USD 327 billion, which was 26% higher than the previous estimate of USD 245 billion. Hence, increasing healthcare spending will impel the revenue inflow for the market.
 

The report emphasizes on growth drivers, as well as restraints that will affect the expansion of this business sphere in the upcoming years. It also analyses relevant data and statistics to help define the present and future revenue trends in this vertical.
 

Moreover, the study quantifies the diabetic population in the United States and provides forecasts for the same through 2027. It then divulges a six-year estimate for blood glucose meter market size in the U.S.
 

An overview of the regulatory framework surrounding the United States self-monitoring blood glucose (SMBG) market enables stakeholders to formulate best suited strategies so as to ensure optimum profitability in the upcoming years.
 

Proceeding further, an in-depth evaluation of present trends and forecasts for the volume of blood glucose test strips users, as well as blood glucose lancets users in the country provides insights into overall remuneration scope of the industry.
 

Considering the competitive landscape, prominent players in the United States self-monitoring blood glucose (SMBG) industry report include F. Hoffmann-La Roche AG, LifeScan IP Holdings LLC, Arkray Inc., ForaCare Inc., Fifty50 Medical LLC, iHealth Labs Inc., Oak Tree Health Center, Teladoc Health Inc. (Livongo), DarioHealth Corp., One Drop Foundation, Sanofi S.A., BioTel Care (Phillips), Walgreen Co., i-SENS Inc., Medtronic plc, US Diagnostics Inc., Omnis Health LLC, Nova Diabetes Care, and Trividia Health Inc. among others.